Dynavax Announces Strategic Restructuring to Focus on its Vaccine Business – GlobeNewswire
Company will explore strategic alternatives for its immuno-oncology programs Company will align its resources to focus on HEPLISAV-B commercialization Eddie Gray, CEO, to retire BERKELEY, Calif., May 23, 2019 (GLOBE NEWSWIRE) — Dynavax Technologies Corporation (NASDAQ: DVAX), today announced a strategic restructuring to prioritize its vaccine business by focusing on the companys first commercial product…